| abstract |
Methods of treating cancer are described, including administering an extracellular domain (ECD) of fibroblast growth factor 1 receptor (FGFR1) and / or an FCD FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed and bevacizumab. Dose packages are also described including FGFR1 ECD and / or the FGFR1 ECD fusion molecule and / or at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU) , leucovorin, pemetrexed and bevacizumab. In some embodiments, the dose package includes instructions for administering the FGFR1 ECD and / or the FGFR1 ECD fusion molecule with at least one additional therapeutic agent. |